Ninety One UK Adds $79M in Boston Scientific Corporation ($BSX)
Key Points
- Ninety One UK changed its Boston Scientific Corporation ($BSX) stake by 34.24% last quarter, boosting to 7,308,540 shares worth $311.38 million.
- Wall Street's consensus rating on $BSX is Buy and an average price target of $62.69.
- $BSX last traded around $42.60.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Ninety One UK increased its position in Boston Scientific Corporation ($BSX) by 34.24% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,308,540 shares of Boston Scientific Corporation after buying 1,863,991 shares during the quarter. Ninety One UK's holdings in Boston Scientific Corporation were worth $311.38 million as of its most recent filing.
Boston Scientific Corporation Stock Down 9.0%
Shares of Boston Scientific Corporation ($BSX) traded around $42.60 on Saturday, down 9.0% for the day.
Boston Scientific Corporation Earnings
Analysts Set New Price Targets
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Get Boston Scientific Corporation alerts
New 13F filings, insider trades, and analyst moves on $BSX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.